Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5492 in Relapsed or Refractory B-Cell Malignancies
NCT06542250Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Primary completion
- Dec 2029
- Modality
- Small Molecules, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of AZD5492 in B-cell malignancy, sponsored by AstraZeneca. Started Sep 2024; status: recruiting.
02
Drugs
AZD5492
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT06542250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06542250.